TheEdgeResearch
Home / Stocks / RDY

Dr. Reddy's Laboratories Limited (RDY)

NYSE Healthcare Drug Manufacturers - Specialty & Generic
$12.57 ▲ +1.37%
Market Cap
$10.47B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.25
52-Wk Range
11.36-15.67
CEO
Erez Israeli
Country
IN
Currency
USD

Dr. Reddy's Laboratories Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hyderabad, TS, IN. The stock last traded at $12.57, up 1.37% on the session, giving a market capitalisation of $10.47B. On trailing twelve-month figures it carries a trailing P/E of 30.49, a net margin of 10.0%. Its beta of 0.25 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
30.49
Price / Sales
3.05
Price / Book
2.63
EV / EBITDA
16.04
Gross margin
50.2%
Operating margin
10.6%
Net margin
10.0%
Return on equity
Debt / equity
0.19
Current ratio
1.90
Dividend yield
0.7%
Payout ratio
20.1%
Company profile
Exchange
New York Stock Exchange
Employees
27,527
IPO date
2001-04-11
Headquarters
Hyderabad, TS, IN
About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.

Comparable companies

Dr. Reddy's Laboratories Limited is most often compared with the following Healthcare names:

BMRNEHCELANENSGEXELNBIXRVMDRVTYSOLVVTRS
More research on RDY
RDY technical analysis RDY TheEdge Score Compare against peers
Open full interactive analysis & DCF →